Edited by:
H. Tristram
Engelhardt, Jr., Department of Philosophy,
Rice University, and Professor Emeritus Department
of Medicine, Baylor College of Medicine, Houston,
TX, USA and Jeremy
R. Garrett, Department of
Philosophy, California State University, Sacramento, CA, USA
Audience:
- Professionals (managers,
scientists, lawyers) working in drug development
in the
pharmaceutical
industry.
- Business ethicists and bioethicists in business,
academic, and industry settings.
- Health policy
experts
- Health lawyers
Description:
Innovation and
the Pharmaceutical Industry: Critical Reflections
on the Virtues of Profit examines
the central role of profit in the development
of pharmaceuticals,
medical devices, and health care generally.
Recent efforts to understand this role have
often underestimated and even dismissed its
importance, arguing for its replacement by
other means and mechanisms. However, as the
essays in this volume attest, it would be impossible
to account adequately for the range of pharmaceuticals
and medical devices that have become part of
everyday medicine without recognizing that
the depth and scope of innovations are tied
not simply to altruism, a concern for the common
good, or the pursuit of knowledge for its own
sake, but crucially to the pursuit of private
good and of individual profit.
Balancing
a concern for theory and practice, the analyses
and evaluations
provided in these
essays touch directly on many of the most
heated and important debates in pharmaceutical
ethics,
such as profit margins, corporate social
responsibility, drug advertising, litigation,
patents, and
parallel trade. Reflecting critically on
the problems and prospects of medical innovation,
they invite a rethinking of the foundations
of the bioethics and business ethics of the
pharmaceutical and medical device industries
by focusing on the long-term impact of policy
decisions for human health and well-being. About
the Editor:
H.
Tristram Engelhardt, Jr., holds degrees
in both medicine and philosophy. He is
Professor in the Department of Philosophy
at Rice University, Professor Emeritus
in the Department of Medicine, Baylor College
of Medicine. In addition to having authored
over 300 articles and chapters of books,
as well as having authored or co-edited
more than 30 volumes, he is the senior
editor of The Journal of Medicine and Philosophy.
Jeremy R. Garrett Ph.D.,
Department of Philosophy, California State University, Sacramento
Table
of Contents:
Martin D. Beirne: Preface.
I. INTRODUCTION
H.
Tristram Engelhardt, Jr. & Jeremy
R. Garrett: Pharmaceutical Innovation
and the
Market: The Pursuit of Profit and the Amelioration
of the Human Condition.
II. THE SOCIAL RESPONSIBILITY
OF PURSUING PROFIT
H.
Tristram Engelhardt, Jr.: The Unavoidable
Goodness of Profit: The Cunning of Reason
and the Realization of Human Well-Being. Nicholas
Capaldi: Corporate Social Responsibility and
Business Ethics
in the Pharmaceutical
Industry.
Pepe
Lee Chang: Pharmaceutical
Companies and Their Obligations to Developing Countries: Psychopaths or Scapegoats?
III.
AUTONOMY, ADVERTISING, AND PHARMACEUTICAL
COSTS James
Stacy Taylor: Autonomy, Constraining
Options, and Pharmaceutical Costs.
Andrew
I. Cohen: Pharmaceutical Advertising
and Patient Autonomy.
IV. SOME CRITICISMS
OF THE PHARMACEUTICAL INDUSTRY CRITICALLY
RE-EXAMINED
Richard
A. Epstein: Why America does not have a Second Drug Problem?
Michael
A. Rie: Global Drug Innovation
in a World of Financial Finitude:
Retailing
Virtue to Promote Capital Formation and
Profit.
V.
MARKETS, PHARMACEUTICALS, AND HEALTH SAVINGS
ACCOUNTS John
C. Goodman: Time, Money, and the Market for Drugs.
John
R. Graham: Perils of Parallel Trade:
Reimporting Prescription Drugs
from Canada
to the U.S.
VI. PHARMACEUTICAL
LIABILITY: ANOTHER SOURCE OF HEALTH
CARE COSTS
Sandra
H. Johnson & Ana
Smith Iltis: Risk, Responsibility,
and Litigation.
|
